SG11202101486RA - Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation - Google Patents
Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparationInfo
- Publication number
- SG11202101486RA SG11202101486RA SG11202101486RA SG11202101486RA SG11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA SG 11202101486R A SG11202101486R A SG 11202101486RA
- Authority
- SG
- Singapore
- Prior art keywords
- substitued
- imidazo
- amino
- preparation
- improved methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/68—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765094P | 2018-08-16 | 2018-08-16 | |
| US201862720970P | 2018-08-22 | 2018-08-22 | |
| PCT/US2019/046594 WO2020037094A1 (en) | 2018-08-16 | 2019-08-15 | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202101486RA true SG11202101486RA (en) | 2021-03-30 |
Family
ID=67809671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202101486RA SG11202101486RA (en) | 2018-08-16 | 2019-08-15 | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11572360B2 (en) |
| EP (1) | EP3837245A1 (en) |
| JP (1) | JP2021534180A (en) |
| KR (1) | KR20210046022A (en) |
| CN (1) | CN112888677A (en) |
| AU (1) | AU2019321470A1 (en) |
| BR (1) | BR112021002642A2 (en) |
| CA (1) | CA3109778A1 (en) |
| IL (1) | IL280823A (en) |
| MX (1) | MX2021001581A (en) |
| SG (1) | SG11202101486RA (en) |
| WO (1) | WO2020037094A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE922316A1 (en) | 1991-07-17 | 1993-01-27 | Smithkline Beecham Corp | Retroviral protease inhibitors |
| BRPI9916853B8 (en) | 1998-12-23 | 2021-05-25 | Abgenix Inc | monoclonal antibody or an antigen-binding fragment thereof that specifically binds to cytotoxic t-lymphocyte antigen 4 (ctla-4) and nucleic acid |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| WO2006009832A1 (en) | 2004-06-18 | 2006-01-26 | 3M Innovative Properties Company | Substituted imidazo ring systems and methods |
| PT1907424E (en) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US8410155B2 (en) | 2006-12-15 | 2013-04-02 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors |
| US20140249135A1 (en) | 2007-03-01 | 2014-09-04 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| ES2616355T3 (en) | 2007-06-18 | 2017-06-12 | Merck Sharp & Dohme B.V. | Antibodies for the human programmed death receptor PD-1 |
| US8562945B2 (en) | 2008-01-09 | 2013-10-22 | Molecular Insight Pharmaceuticals, Inc. | Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof |
| KR20180089573A (en) | 2008-12-09 | 2018-08-08 | 제넨테크, 인크. | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101740171B1 (en) | 2009-11-24 | 2017-05-25 | 메디뮨 리미티드 | Targeted binding agents against b7-h1 |
| US20130296311A1 (en) | 2010-05-28 | 2013-11-07 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| HU1000676D0 (en) | 2010-12-17 | 2011-02-28 | Pharmahungary 2000 Kft | Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved |
| JP6072771B2 (en) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Antibodies and other molecules that bind to B7-H1 and PD-1 |
| KR20120122705A (en) | 2011-04-29 | 2012-11-07 | 주식회사 레고켐 바이오사이언스 | Imidazole-based Alkaloid Derivatives for Inhibition of Angiogenesis and anti-oxidant activity, and Methods for Preparing them |
| KR101764096B1 (en) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | Anti-pd-l1 antibodies and uses thereof |
| US9856320B2 (en) | 2012-05-15 | 2018-01-02 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| EP2854843A4 (en) | 2012-05-31 | 2016-06-01 | Sorrento Therapeutics Inc | Antigen binding proteins that bind pd-l1 |
| EP3770176A1 (en) | 2013-05-02 | 2021-01-27 | AnaptysBio, Inc. | Antibodies directed against programmed death-1 (pd-1) |
| JP6453855B2 (en) | 2013-05-18 | 2019-01-16 | アドゥロ バイオテック，インク． | Compositions and methods for activating "interferon gene stimulator" dependent signaling |
| CN105683217B (en) | 2013-05-31 | 2019-12-10 | 索伦托治疗有限公司 | Antigen binding proteins that bind to PD-1 |
| PT3702373T (en) | 2013-09-13 | 2022-09-27 | Beigene Switzerland Gmbh | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
| AR094537A1 (en) * | 2013-11-07 | 2015-08-12 | Bristol Myers Squibb Co | PIRIDIL COMPOUNDS REPLACED WITH USEFUL ALQUILAMIDE AS MODULATORS OF THE ANSWERS OF IL-12, IL-23 AND / OR IFNa |
| JP6502959B2 (en) | 2013-12-12 | 2019-04-17 | 上海恒瑞医薬有限公司 | PD-1 antibodies, antigen binding fragments thereof and their medical use |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
| WO2015162075A1 (en) | 2014-04-22 | 2015-10-29 | F. Hoffmann-La Roche Ag | 4-amino-imidazoquinoline compounds |
| AU2015291788A1 (en) | 2014-07-16 | 2016-11-24 | Novogen ltd | Functionalised and substituted carbazoles as anti-cancer agents |
| KR20170083136A (en) | 2014-11-18 | 2017-07-17 | 머크 샤프 앤드 돔 코포레이션 | Aminopyrazine compounds with a2a antagonist properties |
| JP6826055B2 (en) | 2015-03-13 | 2021-02-03 | サイトメックス セラピューティクス インコーポレイテッド | Anti-PDL1 antibody, activating anti-PDL1 antibody, and how to use it |
| SI3303394T1 (en) | 2015-05-29 | 2020-10-30 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (en) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH) |
| SG10201913276WA (en) | 2015-09-01 | 2020-02-27 | Agenus Inc | Anti-pd-1 antibodies and methods of use thereof |
| WO2017102091A1 (en) | 2015-12-18 | 2017-06-22 | Bayer Pharma Aktiengesellschaft | Heteroarylbenzimidazole compounds |
| EP3402255B1 (en) | 2016-02-02 | 2021-03-31 | Huawei Technologies Co., Ltd. | Emission power verification method, user equipment, and base station |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| WO2017160922A1 (en) | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| US10533007B2 (en) | 2016-04-19 | 2020-01-14 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| JP7104633B6 (en) | 2016-04-19 | 2023-12-22 | イネイト・テューマー・イミュニティ・インコーポレイテッド | NLRP3 modifier |
| TWI674261B (en) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 modulators |
| AU2018358160B2 (en) | 2017-11-02 | 2023-03-16 | Abbvie Inc. | Modulators of the integrated stress pathway |
| SG11202101486RA (en) | 2018-08-16 | 2021-03-30 | Innate Tumor Immunity Inc | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation |
| ES2974964T3 (en) | 2018-08-16 | 2024-07-02 | Innate Tumor Immunity Inc | Imidazo[4,5-c]quinoline-derived NLRP3 modulators |
| KR20210046023A (en) | 2018-08-16 | 2021-04-27 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Imidazo[4,5-c]quinoline-derived NLRP3-modulator |
-
2019
- 2019-08-15 SG SG11202101486RA patent/SG11202101486RA/en unknown
- 2019-08-15 US US17/268,725 patent/US11572360B2/en active Active
- 2019-08-15 KR KR1020217007428A patent/KR20210046022A/en unknown
- 2019-08-15 CA CA3109778A patent/CA3109778A1/en not_active Abandoned
- 2019-08-15 BR BR112021002642-8A patent/BR112021002642A2/en not_active Application Discontinuation
- 2019-08-15 JP JP2021507851A patent/JP2021534180A/en active Pending
- 2019-08-15 WO PCT/US2019/046594 patent/WO2020037094A1/en unknown
- 2019-08-15 CN CN201980067722.XA patent/CN112888677A/en active Pending
- 2019-08-15 MX MX2021001581A patent/MX2021001581A/en unknown
- 2019-08-15 EP EP19762009.9A patent/EP3837245A1/en not_active Withdrawn
- 2019-08-15 AU AU2019321470A patent/AU2019321470A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280823A patent/IL280823A/en unknown
-
2022
- 2022-11-22 US US17/991,875 patent/US11827597B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3109778A1 (en) | 2020-02-20 |
| MX2021001581A (en) | 2021-04-19 |
| AU2019321470A1 (en) | 2021-04-01 |
| JP2021534180A (en) | 2021-12-09 |
| WO2020037094A1 (en) | 2020-02-20 |
| IL280823A (en) | 2021-04-29 |
| US20230097144A1 (en) | 2023-03-30 |
| KR20210046022A (en) | 2021-04-27 |
| US11572360B2 (en) | 2023-02-07 |
| CN112888677A (en) | 2021-06-01 |
| BR112021002642A2 (en) | 2021-05-04 |
| US11827597B2 (en) | 2023-11-28 |
| EP3837245A1 (en) | 2021-06-23 |
| US20210332040A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290276A (en) | Tetracyclic compound, preparation method and use thereof | |
| IL257886B (en) | Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors | |
| EP3621613A4 (en) | Aminopyridine compounds and methods for the preparation and use thereof | |
| EP3439658A4 (en) | SOLUBLE C5aR ANTAGONISTS | |
| IL280182A (en) | Pyridin-2-one compounds useful as smarca2 antagonists | |
| HK1255408A1 (en) | 8-[6-[3-(amino)propoxy]-3-pyridyl]-1 -isopropyl-imidazo[4,5-c]quinolin-2-one derivatives as selective modulators of ataxia telangiectasia mutated (atm) kinase for the treatment of cancer | |
| EP3154970A4 (en) | Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles | |
| IL251164B (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| AU2017435893B2 (en) | Methods for the administration of certain VMAT2 inhibitors | |
| IL279662A (en) | Methods for the administration of certain vmat2 inhibitors | |
| IL269214B (en) | Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors | |
| EP3421038A4 (en) | Naphthyridine compound, pharmaceutical composition and use thereof | |
| IL283762A (en) | Naphthyridine and quinoline derivatives useful as alk5 inhibitors | |
| EP3752149A4 (en) | Quinolone analogs and their salts, compositions, and method for their use | |
| EP3790864A4 (en) | Quinoline derivatives and preparation methods and uses thereof | |
| EP3508483A4 (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| IL251166A0 (en) | Imidazo[4,5-c]pyridine derived ssao inhibitors | |
| EP3808751A4 (en) | Camptothecin derivative, preparation method therefor and application thereof | |
| EP3694488A4 (en) | Hydroxychloroquine sulfate formulations and methods for preparation and use thereof | |
| IL271233A (en) | Substituted quinolinycyclohexylpropanamide compounds and improved methods for their preparation | |
| IL280823A (en) | Substitued 4-amino-1h-imidazo[4,5-c]quinoline compounds and improved methods for their preparation | |
| EP3491128A4 (en) | Methods and compositions for preventing concatemerization during template- switching | |
| IL269215A (en) | Cyclic substituted imidazo[4,5-c]quinoline derivatives | |
| EP3302060A4 (en) | Pyrazolo[4,3-c]quinoline derivatives for inhibition of -glucuronidase | |
| EP3522757A4 (en) | Self-making bedding system, method and kit thereof |